#1 Clinical Trials Search in Europe

4-{5-[2-(4-Chloro-2,6-Difluorophenoxy)Propan-2-Yl]-4-Methyl-4H-1,2,4-Triazol-3-Yl}-3-Fluorobenzamide

This article summarizes clinical trials investigating the use of SPI-62, a novel drug also known as 4-{5-[2-(4-Chloro-2,6-Difluorophenoxy)Propan-2-Yl]-4-Methyl-4H-1,2,4-Triazol-3-Yl}-3-Fluorobenzamide, for treating Cushing’s syndrome and related conditions. SPI-62 is being studied as a potential treatment for excessive cortisol levels in patients with various forms of Cushing’s syndrome, as well as in combination with prednisolone for polymyalgia rheumatica. The trials aim to evaluate the safety, efficacy, and pharmacological effects of SPI-62 in these patient populations.

Table of Contents

Introduction

SPI-62, also known as Clofutriben, is a novel medication currently being studied for the treatment of various conditions related to excessive cortisol levels in the body. This article will provide an overview of SPI-62, its mechanism of action, and the ongoing clinical trials investigating its potential benefits for patients with Cushing’s syndrome and other related disorders.

What is SPI-62?

SPI-62 is a new drug developed by Sparrow Pharmaceuticals, Inc. Its chemical name is 4-{5-[2-(4-chloro-2,6-difluorophenoxy)propan-2-yl]-4-methyl-4H-1,2,4-triazol-3-yl}-3-fluorobenzamide[1]. It is also known by other names such as Clofutriben and ASP3662[2]. SPI-62 is administered orally as a film-coated tablet.

How Does SPI-62 Work?

SPI-62 is a potent and selective inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (HSD-1)[1]. HSD-1 is an enzyme that plays a crucial role in converting inactive cortisone to active cortisol in the body. By inhibiting this enzyme, SPI-62 aims to reduce the excessive cortisol levels associated with various medical conditions, particularly Cushing’s syndrome.

Conditions Treated by SPI-62

SPI-62 is being investigated for the treatment of several conditions related to excessive cortisol levels:

  • Cushing’s Syndrome: A hormonal disorder caused by prolonged exposure to high levels of cortisol[1].
  • ACTH-dependent Cushing’s Syndrome: Including Cushing’s disease, ectopic ACTH secretion, and ectopic corticotrophin-releasing hormone (CRH) secretion[1].
  • Hypercortisolism related to benign adrenal tumors: Excessive cortisol production due to autonomous cortisol secretion (ACS) from benign adrenal lesions[2].
  • Polymyalgia Rheumatica (PMR): A inflammatory disorder that causes muscle pain and stiffness, often treated with corticosteroids like prednisolone[3].

Clinical Trials

Several clinical trials are currently underway to evaluate the safety and efficacy of SPI-62:

  1. ACTH-dependent Cushing’s Syndrome Trial: This study aims to characterize the pharmacologic effect of SPI-62 in patients with ACTH-dependent Cushing’s syndrome, including Cushing’s disease and ectopic ACTH/CRH secretion[1].
  2. Hypercortisolism Related to Benign Adrenal Tumor Trial: This trial is studying the benefit-risk profile of SPI-62 in patients with complications due to hypercortisolism related to autonomous cortisol secretion (ACS) from benign adrenal tumors[2].
  3. Polymyalgia Rheumatica (PMR) Trial: This study is investigating the use of SPI-62 in combination with prednisolone for patients with PMR, aiming to determine if SPI-62 can help reduce the required dose of prednisolone while maintaining efficacy and potentially reducing side effects[3].

Potential Benefits of SPI-62

The ongoing clinical trials are exploring several potential benefits of SPI-62:

  • Reduction of excessive cortisol levels in patients with Cushing’s syndrome and related conditions[1].
  • Improvement in various symptoms and complications associated with hypercortisolism, such as hyperglycemia, dyslipidemia, hypertension, and osteoporosis[1][2].
  • Potential to reduce the required dose of corticosteroids (like prednisolone) in conditions such as PMR, which may help minimize side effects associated with long-term corticosteroid use[3].
  • Possible improvements in mood, cognition, and overall quality of life for patients with cortisol-related disorders[1].

Possible Side Effects

As SPI-62 is still in clinical trials, the full range of potential side effects is not yet known. The ongoing studies are closely monitoring for any adverse events, including:

  • Changes in hypothalamic-pituitary-adrenal (HPA) axis function[1].
  • Effects on the hypothalamic-pituitary-gonadal (HPG) axis[1].
  • Any unexpected changes in laboratory values, vital signs, or other clinical parameters[1][2].

It’s important to note that the safety profile of SPI-62 will be more clearly understood as the clinical trials progress and more data becomes available.

Conclusion

SPI-62 (Clofutriben) represents a promising new approach to treating conditions associated with excessive cortisol levels, such as Cushing’s syndrome and related disorders. By inhibiting the enzyme responsible for converting inactive cortisone to active cortisol, SPI-62 aims to address the root cause of these conditions. Ongoing clinical trials will provide more information about its efficacy, safety, and potential benefits for patients. As research continues, SPI-62 may offer new hope for individuals struggling with the challenging symptoms and complications of cortisol-related disorders.

Trial Name Condition Main Objective Key Endpoints
2024-515913-17-00 ACTH-dependent Cushing’s syndrome Evaluate pharmacologic effect of SPI-62 Urinary HSD-1 ratio, safety, clinical parameters
2024-516785-12-00 Hypercortisolism related to benign adrenal tumor Study benefit-risk profile of SPI-62 Safety, disease progression/regression, clinical signs
2024-517406-29-00 Polymyalgia rheumatica (PMR) Assess prednisolone dose adjustment with SPI-62 Inflammatory markers, glucose tolerance, bone markers

FAQ

  • What is SPI-62? SPI-62 is a new drug being studied to treat conditions related to high cortisol levels. It works by blocking an enzyme called 11β-hydroxysteroid dehydrogenase type 1 (HSD-1), which is involved in cortisol production in the body.
  • What conditions is SPI-62 being tested for? SPI-62 is being tested for Cushing's syndrome (including Cushing's disease and ectopic ACTH secretion), hypercortisolism related to benign adrenal tumors, and in combination with prednisolone for polymyalgia rheumatica.
  • How is SPI-62 given to patients? SPI-62 is given as a film-coated tablet that patients take by mouth. The dosage varies depending on the specific trial and condition being studied.
  • What are the main goals of these clinical trials? The main goals are to evaluate the safety and effectiveness of SPI-62, understand how it affects cortisol levels and related symptoms, and determine the appropriate dosing for different conditions.
  • Who can participate in these clinical trials? Eligibility varies by trial, but generally includes adult patients diagnosed with the specific condition being studied (e.g., Cushing's syndrome, polymyalgia rheumatica) who meet certain health criteria. Patients should discuss participation with their doctor.

Ongoing Clinical Trials on 4-{5-[2-(4-Chloro-2,6-Difluorophenoxy)Propan-2-Yl]-4-Methyl-4H-1,2,4-Triazol-3-Yl}-3-Fluorobenzamide

  • Study of SPI-62 for Treating Cushing’s Syndrome in Patients with Benign Adrenal Tumors

    Not recruiting

    1 1
    Investigated drugs:
    Romania

Glossary

  • ACTH (Adrenocorticotropic hormone): A hormone produced by the pituitary gland that stimulates the adrenal glands to produce cortisol.
  • Cushing's syndrome: A condition characterized by excessive levels of cortisol in the body, which can be caused by various factors including tumors.
  • Cushing's disease: A specific form of Cushing's syndrome caused by a tumor in the pituitary gland that produces too much ACTH.
  • Cortisol: A hormone produced by the adrenal glands that helps regulate metabolism, immune response, and stress.
  • Hypercortisolism: Another term for excessive cortisol levels in the body.
  • HSD-1 (11β-hydroxysteroid dehydrogenase type 1): An enzyme involved in the production of cortisol in the body, which is targeted by SPI-62.
  • Polymyalgia rheumatica (PMR): An inflammatory disorder causing muscle pain and stiffness, typically in older adults.
  • Prednisolone: A corticosteroid medication used to treat various inflammatory conditions, including polymyalgia rheumatica.
  • Adrenal glands: Small glands located on top of the kidneys that produce hormones, including cortisol.
  • Pituitary gland: A small gland at the base of the brain that produces various hormones, including ACTH.

References

  1. http://clinicaltrials.eu/trial/study-of-spi-62-for-treating-acth-dependent-cushings-syndrome-in-patients-with-cushings-disease-or-ectopic-acth-crh-secretion/
  2. http://clinicaltrials.eu/trial/study-of-spi-62-for-treating-cushings-syndrome-in-patients-with-benign-adrenal-tumors/
  3. http://clinicaltrials.eu/trial/study-of-prednisolone-and-spi-62-for-patients-with-polymyalgia-rheumatica/